Spyre Therapeutics stock tumbles on trial results

Spyre Therapeutics (SYRE) reported mixed Phase 2 results for SPY072 in rheumatoid arthritis, showing efficacy but not meeting monotherapy targets. Both doses showed statistically significant benefits over placebo on some endpoints. The company plans to release data on other trials in 2026-2028. Wedbush maintains an outperform rating with a $130 price target. SYRE shares are down 4.06% in overnight trading.

Intuit (INTU) fell 9% after lowering FY2027 guidance, missing EPS and revenue estimates. Semtech (SMTC) rose 3% on strong Q2 results and raised Q3 outlook. Spyre Therapeutics (SYRE) dropped 16% due to failed clinical trial results. Zoom (ZM) declined 3.5% despite Q2 beat, citing growth normalization. nCino (NCNO) fell 10% on near-term guidance concerns.

Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 spyre-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), d

Spyre Therapeutics (NASDAQ:SYRE) shares fell 13.7% in premarket trading after SEC Form 4 filings showed major insider-related sales. Fairmount Healthcare Fund II L.P., affiliated with Spyre directors, sold 4,684,781 common shares on June 23 for about $399.7 million, leaving zero common shares. Spyre director Michael Thomas Henderson sold 20,000 shares for about $2 million under a Rule 10b5-1 plan.

Spyre Therapeutics’ (SYRE) shares rose 4.16% to $72.04 on Wednesday after the company said enrollment was completed across all sub-studies in its SKYWAY Phase 2 basket trial of SPY072, an anti-TL1A therapy for rheumatic diseases. The company said enrollment finished in under nine months and keeps it on track for five of six Phase 2 data readouts in 2026.

BNN Bloomberg (May 29) quoted Investment Decision Research’s Melissa Brown saying inflation above the Fed’s 2% target is pressuring bond yields and could weigh on stocks and bonds. She cited strong Q1 earnings partly from a “stock market wealth effect” amid low consumer sentiment (44.8). The article lists 12 high short-interest stocks; examples include Bentley Systems (Q1 2026 revenue $424.2M, FCF $187.9M) and Spyre Therapeutics (pro forma cash $1.2B).